PharVision Advisers’s KRONOS Worldwide KRO Stock Holding History

PharVision Advisers’s Portfolio KRO Stock Details KRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,448	Closed	-$68.6K	–	99
2026 Q1	$68.6K	Buy	+10,448	New	+$59.3K	0.7%	76

Other funds holding KRO

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PharVision Advisers's KRO Position: Q2 2026 in Review

PharVision Advisers sold out of KRONOS Worldwide (KRO) in Q2 2026, closing a stake of 10,448 shares — an estimated $68.6K sold.

PharVision Advisers first reported a position in KRO in Q1 2026 and held it in 1 quarter. The position peaked at $68.6K in Q1 2026. 133 funds tracked by Wall St. Rank hold KRO as of Q2 2026.

PharVision Advisers reported no remaining KRONOS Worldwide position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 10,448 KRONOS Worldwide shares in Q2 2026, an estimated $68.6K.
PharVision Advisers first reported a position in KRONOS Worldwide in Q1 2026 and held it in 1 quarter.
PharVision Advisers's KRONOS Worldwide position peaked at $68.6K in Q1 2026.
133 funds tracked by Wall St. Rank held KRONOS Worldwide as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.